"Liver Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the LIVER.
| Descriptor ID |
D008113
|
| MeSH Number(s) |
C04.588.274.623 C06.301.623 C06.552.697
|
| Concept/Terms |
Liver Neoplasms- Liver Neoplasms
- Neoplasms, Hepatic
- Neoplasms, Liver
- Liver Neoplasm
- Neoplasm, Liver
- Hepatic Neoplasms
- Hepatic Neoplasm
- Neoplasm, Hepatic
Cancer of Liver- Cancer of Liver
- Hepatocellular Cancer
- Cancers, Hepatocellular
- Hepatocellular Cancers
- Hepatic Cancer
- Cancer, Hepatic
- Cancers, Hepatic
- Hepatic Cancers
- Liver Cancer
- Cancer, Liver
- Cancers, Liver
- Liver Cancers
- Cancer of the Liver
- Cancer, Hepatocellular
|
Below are MeSH descriptors whose meaning is more general than "Liver Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Liver Neoplasms".
This graph shows the total number of publications written about "Liver Neoplasms" by people in this website by year, and whether "Liver Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 6 | 0 | 6 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 8 | 2 | 10 |
| 2011 | 8 | 1 | 9 |
| 2012 | 4 | 2 | 6 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 6 | 1 | 7 |
| 2016 | 6 | 2 | 8 |
| 2017 | 6 | 1 | 7 |
| 2018 | 1 | 0 | 1 |
| 2019 | 6 | 0 | 6 |
| 2020 | 5 | 2 | 7 |
| 2021 | 4 | 0 | 4 |
| 2022 | 8 | 0 | 8 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Neoplasms" by people in Profiles.
-
Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents. J Med Chem. 2024 Sep 26; 67(18):16270-16295.
-
Targeting SMOX for the treatment of hepatocellular carcinoma? Clin Res Hepatol Gastroenterol. 2024 10; 48(8):102429.
-
From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases. Int J Mol Sci. 2024 Jun 12; 25(12).
-
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135.
-
High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. World J Gastroenterol. 2022 Sep 21; 28(35):5217-5229.
-
Senolytic treatment reduces cell senescence and necroptosis in Sod1 knockout mice that is associated with reduced inflammation and hepatocellular carcinoma. Aging Cell. 2022 Aug; 21(8):e13676.
-
Human liver organoids for disease modeling of fibrolamellar carcinoma. Stem Cell Reports. 2022 08 09; 17(8):1874-1888.
-
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
-
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
-
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022 10; 76(4):1000-1012.